Kalofonos Isabel 4
4 · Crinetics Pharmaceuticals, Inc. · Filed Feb 25, 2026
Insider Transaction Report
Form 4
Kalofonos Isabel
Chief Commercial Officer
Transactions
- Award
Common Stock
[F1]2026-02-23+34,000→ 34,834 total - Award
Stock Option (Right to Buy)
[F2]2026-02-23+55,000→ 55,000 totalExercise: $43.79Exp: 2036-02-23→ Common Stock (55,000 underlying)
Footnotes (2)
- [F1]The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2027.
- [F2]The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 23, 2026.
Signature
/s/ Tobin Schilke, as attorney-in-fact|2026-02-25